



ALK
Investor Relations Department
BÃge Alle 6-8
Horsholm DK-2970
Denmark

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

OMX: ALKB

| | |
|---------------|---|
| Last Trade: | 783.00 |
| Trade Time: | 4:59 PM ET Apr 20, 2018 |
| Change: | 12.00 ▲ (+1.556%) |
| Day Range | 769.00 - 785.00 |
| 52-Week Range | 646.00 - 1133.00 |
| Volume | 1,380,600 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

ALK is the world leader in allergy vaccination (immunotherapy). It is the goal of ALK to increase the awareness of the company and its activities through a structured, ongoing, timely and balanced dialogue with investors, shareholders and other stakeholders. It is also a company goal to secure the liquidity of the company's shares and to generate reasonable, long-term returns to shareholders through share price increases and dividends.... [\(more\)](#)

Company releases [\[View all \]](#)

- Apr 17, 2018*
[ALK's partner for Japan, Torii, secures pricing for new Japanese cedar SLIT-tablet](#)
- Apr 11, 2018*
[ALK announces allergy diagnostic partnership with Rellerger in China](#)
- Mar 20, 2018*
[Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff](#)
- Mar 20, 2018*
[Grant of share options and performance shares to members of the Board of Management and key employees](#)
- Mar 16, 2018*
[Articles of Association](#)

Upcoming Events [\[View all \]](#)

- May 4, 2018*
[Three-month interim report \(Q1\) 2018](#)
- Aug 15, 2018*
[Six-month interim report \(Q2\) 2018](#)